A collaborative, 3D bioprinting project co-led by Taciana Pereira, S.B. ’17 (engineering sciences - bioengineering) will help combat COVID-19.
Allevi, Inc., a Philadelphia based startup pioneering innovative 3D biofabrication technologies, has joined forces with The Wistar Institute, a biomedical research leader in cancer, immunology, and infectious diseases, to study SARS-CoV-2 mechanisms of disease progression.
Allevi will apply its patented 3D bioprinting platform to create three-dimensional lung models that Wistar scientists will use to study SARS-CoV-2, the virus that causes COVID-19. The goal will be to investigate the mechanisms deployed by this pathogen to infect humans and identify potential ways in which it may be blocked. Pereira, Allevi Vice President of Life Sciences, is a co-principal investigator on the project.
Press Contact
Adam Zewe | 617-496-5878 | azewe@seas.harvard.edu